Indian CRAM market to clock $ 7.6 billion by 2012

10 Jun 2011 Evaluate

The Indian custom research and manufacturing segment is expected to reach a market size of $ 7.6 billion by 2012, with custom manufacturing leading the pack. The growth will be supported by, among other things, the high number of plants approved by the United States regulatory authority – the Food and Drug Administration; skilled manpower and the inherent cost advantages that enable India to capture a significant chunk of the current $ 67 billion global pharma outsourcing market.

The global outsourcing market is expected to grow at a compounded annual growth rate 12.6 percent during FY10-12 to reach a market size of $ 85 billion by FY12. In the same period, the Indian CRAM (custom research and manufacturing segment) is growing at about 41 percent. The growth of the outsourcing opportunity is being propelled by the loss of patent protection to the tune of $ 97 billion over 2011-2015; steady erosion in new product launches in relation to research spend and new launches not matching up to the earlier block-busters drugs (or medicines that gross sales of over $ 1 billion).This coupled with the increasing role of generics and pricing pressure played out in the developed nations have forced big pharma players to look for cost-containment measures to protect their bottom-line.

Key Indian companies operating in this space include Piramal Healthcare, Biocon Limited, Jubilant Life Sciences and Divi’s lab, who have displayed strong growth over the last few years, though concerns on economic slowdown has led to inventory rationalization by global pharma majors - thus leading to slowdown in growth during FY10 and H1 FY11.crackcrack

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×